399 related articles for article (PubMed ID: 26067326)
1. Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML.
Hornick NI; Huan J; Doron B; Goloviznina NA; Lapidus J; Chang BH; Kurre P
Sci Rep; 2015 Jun; 5():11295. PubMed ID: 26067326
[TBL] [Abstract][Full Text] [Related]
2. Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?
Boyiadzis M; Whiteside TL
Expert Rev Mol Diagn; 2016 Jun; 16(6):623-9. PubMed ID: 27043038
[TBL] [Abstract][Full Text] [Related]
3. AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB.
Hornick NI; Doron B; Abdelhamed S; Huan J; Harrington CA; Shen R; Cambronne XA; Chakkaramakkil Verghese S; Kurre P
Sci Signal; 2016 Sep; 9(444):ra88. PubMed ID: 27601730
[TBL] [Abstract][Full Text] [Related]
4. Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression.
Grimolizzi F; Monaco F; Leoni F; Bracci M; Staffolani S; Bersaglieri C; Gaetani S; Valentino M; Amati M; Rubini C; Saccucci F; Neuzil J; Tomasetti M; Santarelli L
Sci Rep; 2017 Nov; 7(1):15277. PubMed ID: 29127370
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
Skou AS; Juul-Dam KL; Ommen HB; Hasle H
Br J Haematol; 2021 Nov; 195(3):310-327. PubMed ID: 33851435
[TBL] [Abstract][Full Text] [Related]
6. miR-638 in circulating leukaemia cells as a non-invasive biomarker in diagnosis, treatment response and MRD surveillance of acute promyelocytic leukaemia.
Bai Y; Chen C; Guo X; Ding T; Yang X; Yu J; Yang J; Ruan J; Zheng X; Chen Z
Cancer Biomark; 2020; 29(1):125-137. PubMed ID: 32568176
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
Kumar B; Garcia M; Weng L; Jung X; Murakami JL; Hu X; McDonald T; Lin A; Kumar AR; DiGiusto DL; Stein AS; Pullarkat VA; Hui SK; Carlesso N; Kuo YH; Bhatia R; Marcucci G; Chen CC
Leukemia; 2018 Mar; 32(3):575-587. PubMed ID: 28816238
[TBL] [Abstract][Full Text] [Related]
8. Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia.
Lin X; Ling Q; Lv Y; Ye W; Huang J; Li X; Guo Q; Wang J; Li Z; Jin J
Cancer Biomark; 2020; 28(2):151-158. PubMed ID: 32176633
[TBL] [Abstract][Full Text] [Related]
9. Rational biomarker development for the early and minimally invasive monitoring of AML.
Abdelhamed S; Butler JT; Jung S; Chen DW; Jenkins G; Gao L; Lim JY; Klco JM; Horton TM; Kurre P
Blood Adv; 2021 Nov; 5(21):4515-4520. PubMed ID: 34587228
[TBL] [Abstract][Full Text] [Related]
10. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma.
Lee YR; Kim G; Tak WY; Jang SY; Kweon YO; Park JG; Lee HW; Han YS; Chun JM; Park SY; Hur K
Int J Cancer; 2019 Mar; 144(6):1444-1452. PubMed ID: 30338850
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
12. Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.
Jackson JM; Taylor JB; Witek MA; Hunsucker SA; Waugh JP; Fedoriw Y; Shea TC; Soper SA; Armistead PM
Analyst; 2016 Jan; 141(2):640-51. PubMed ID: 26523411
[TBL] [Abstract][Full Text] [Related]
13. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
14. An optimized procedure for exosome isolation and analysis using serum samples: Application to cancer biomarker discovery.
Li M; Rai AJ; DeCastro GJ; Zeringer E; Barta T; Magdaleno S; Setterquist R; Vlassov AV
Methods; 2015 Oct; 87():26-30. PubMed ID: 25814440
[TBL] [Abstract][Full Text] [Related]
15. Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer.
Joyce DP; Kerin MJ; Dwyer RM
Int J Cancer; 2016 Oct; 139(7):1443-8. PubMed ID: 27170104
[TBL] [Abstract][Full Text] [Related]
16. Human acute myeloid leukemia blast-derived exosomes in patient-derived xenograft mice mediate immune suppression.
Hong CS; Danet-Desnoyers G; Shan X; Sharma P; Whiteside TL; Boyiadzis M
Exp Hematol; 2019 Aug; 76():60-66.e2. PubMed ID: 31369790
[TBL] [Abstract][Full Text] [Related]
17. Serum exosomal microRNAs as novel biomarkers for multiple myeloma.
Zhang ZY; Li YC; Geng CY; Zhou HX; Gao W; Chen WM
Hematol Oncol; 2019 Oct; 37(4):409-417. PubMed ID: 31102419
[TBL] [Abstract][Full Text] [Related]
18. Identification of serum miR-34a as a potential biomarker in acute myeloid leukemia.
Huang Y; Zou Y; Lin L; Ma X; Chen H
Cancer Biomark; 2018; 22(4):799-805. PubMed ID: 29945348
[TBL] [Abstract][Full Text] [Related]
19. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia.
Zhi F; Cao X; Xie X; Wang B; Dong W; Gu W; Ling Y; Wang R; Yang Y; Liu Y
PLoS One; 2013; 8(2):e56718. PubMed ID: 23437222
[TBL] [Abstract][Full Text] [Related]
20. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma.
Wang H; Hou L; Li A; Duan Y; Gao H; Song X
Biomed Res Int; 2014; 2014():864894. PubMed ID: 24963487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
